Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Fountain Pharmaceuticals (FPHI) -- Ignore unavailable to you. Want to Upgrade?

To: r. peter Dale who wrote (37)	8/24/1997 2:44:00 PM
From: r. peter Dale	Respond to of 78

Please excuse the back-to back posts: I was scanning through some of the SEC documents posted by Fountain regarding their recent financing arrangement. The following paragraph comes from the SC 13D form filed on 08 August, 1997 (available through Edgar. Note: the 'reporting person' is [are] the new investors; the 'issuer' is Fountain - but don't trust me, use Edgar edgar-online.com ITEM 4 PURPOSE OF TRANSACTION. As a result of these transactions, pursuant to a Stock Purchase and Subscription Agreement and the Certificate of Designation, the Reporting Person will have the ability to elect a majority of the board of directors of the Issuer. In this regard, the purpose of the transaction is to effect an equity investment in the issuer and to thereupon allow existing executive management to continue to operate the business although the Reporting Person will for the foreseeable future control the board of directors. The transactions will effect a change in voting control relative to the board of directors of the Issuer and subject to compliance with Section 14 of the Securities Exchange Act and the rules thereunder, the Reporting Person intends to exercise this voting control to eventually elect a majority of the board and to have that board thereupon effect those management decisions customarily reserved for the board of directors of a Delaware corporation. My spin on this would be that Fountain is now under the control of an executive board whose highest priority is to operate a financially viable company. Recall, the new investors now have a $2,500,000 equity position in the company and the new board will be directly responsible to these investors. I suggest this concern over financial health is in dramatic contrast to the modus operandi of FPHI prior to this financing. Best wishes, Peter

To: r. peter Dale who wrote (37)	4/2/2000 12:52:00 AM
From: scaram(o)uche	Respond to of 78

dailynews.yahoo.com Thursday March 30 6:05 PM ET Day Trader Busted for Posting Bogus Lucent Release By Gail Appleson, Law Correspondent NEW YORK (Reuters) - A securities day-trader who allegedly posted a bogus press release on the Internet last week that led to a drop in the price of Lucent Technologies Inc.'s (NYSE:LU - news) shares was arrested on Thursday and charged with securities fraud, the U.S. attorney's office said. Fred Moldofsky, 43, was to be presented in federal court in Houston, Texas, on the charges that were filed in Manhattan federal court, prosecutors said. If convicted he faces a possible maximum sentence of 10 years in prison and a fine of $1 million. The Securities and Exchange Commission also filed a related civil suit against Moldofsky in Manhattan federal court. The complaint said that Moldofsky posted the fraudulent press release, which stated that Lucent Technologies expected an earnings shortfall, on a Yahoo! Inc. message board last Wednesday night. The day after the posting, Lucent's stock price fell by as much as 3.6 percent, representing a reduction of more than $7.1 billion in its market capitalization, prosecutors said. Lucent quickly assured investors it expected to meet expectations for second-quarter earnings, dismissing rumors that had been fueled by the fake press release. Moldofsky, who describes himself on an Internet Web site as a ``full-time online stock investor,' allegedly traded 6,000 shares of Lucent stock the day he issued the bogus press release. The complaint alleged that Moldofsky identified himself with the screen name ``hot-like-wasabe' and sent a message captioned ``LUCENT RELEASES EARNINGS WARNING! DAMN!' Attached to the message was the fake press release that was modeled after a legitimate release issued by Lucent on Jan. 6 in which the company issued an earnings warning with respect to the first quarter of its fiscal year 2000. In an apparent effort to bolster belief in the legitimacy of the press release, Moldofsky also posted numerous messages on the Lucent bulletin board. These messages included ``links' that allowed readers to access the fraudulent press release. The messages were captioned with phrases like ``LUCENT WARNS!' WE'RE ALL DOOMED TOMORROW!' The SEC suit said that between the evening of March 22 and the next morning, Moldofsky reposted that press release 20 times using another name ``Floydian-us,' which was designed to resemble a screen name used by a frequent commentator on the Lucent message board who had expressed a positive view of Lucent stock. Law enforcement officers were able to identify Moldofsky, who lives in Houston, by collecting evidence from Yahoo, America Online (NYSE:AOL - news) and Moldofsky's Internet service provider. (snip)

To: r. peter Dale who wrote (37)	8/25/2000 11:39:17 AM
From: scaram(o)uche	Respond to of 78

Ron: Here's a little blurb. Sounds like a Fisner stock, but perhaps Courtney, Wesley, Aur, Scott or one of their friends have a position?...... DJ: EMLX release a hoax --11:10 am - By Michael Baron The Dow Jones News Service is reporting that an Emulex (EMLX: news, msgs) spokesperson has said that the press release saying the company would restate its earnings is a hoax. The press release, which was apparently issued through something called The Internet Wire via COMTEX, said Emulex would restate its earnings and that the CEO would leave due to an SEC investigation into its accounting practices. The shares remain halted at 55 35/64, down 50.9 percent.

To: r. peter Dale who wrote (37)	8/31/2000 12:06:10 PM
From: scaram(o)uche	Respond to of 78

Ron: CNBC is reporting that an arrest has been made in the Emulex scam, and that it's a man. I guess it wasn't Courtney. Rick

To: r. peter Dale who wrote (37)	8/31/2000 12:34:18 PM
From: scaram(o)uche	Respond to of 78

Ron: It is a student in El Segundo, however. Certainly fits Courtney's profile, otherwise. Hey, maybe Courtney is a man!!??!! Rick

To: r. peter Dale who wrote (37)	9/24/2000 6:02:37 PM
From: scaram(o)uche	Respond to of 78

Ron: I'll just keep posting the fraud stuff here. Certain that you, Mark, Courtney, Scott, Wesley et al. won't mind. This one even has the old "various aliases". No bogus press release this time, however....... Thursday September 21 11:00 AM EDT Teen settles in online stock fraud case By Sam Ames, CNET News.com The Securities and Exchange Commission has settled a civil fraud suit against a 15-year-old boy who allegedly used the Internet in a "pump-and-dump" stock scheme that netted profits of $272,826. According to the SEC, which has never before brought charges against a minor, the boy purchased large blocks of inexpensive microcap stocks. He then used various aliases to promote, or pump up, the stocks on message-board postings before quickly selling, or dumping, the shares for a profit. The SEC said the youth made the first trades and postings when he was 14. In some cases, he allegedly set triggers that would automatically sell the shares at certain levels so as not to miss out on any run-ups while at school. The Cedar Grove, N.J., teen claimed in one of his messages, which were primarily posted on Yahoo Finance, that a company trading at $2 per share would be trading at more than $20 per share "very soon," according to the SEC. Other postings claimed that a stock would be the "next stock to gain 1,000 percent" and was "the most undervalued stock ever." In at least 11 different instances between Aug. 23, 1999, and Feb. 4, 2000, the pumped-up shares rose in value. In some cases the stocks reached a 52-week high for both volume and price, at which point the boy dumped the shares for profits of between $11,000 and $74,000. Without admitting or denying the charges, the minor agreed to follow an administrative cease-and-desist order and to pay back his illegal profits of $272,826, together with prejudgment interest of $12,174, for a total of $285,000. Ronald Long, administrator of the SEC's Philadelphia District Office, urged investors "to be highly skeptical of any advice they receive from the Internet. People should do thorough research before making investment decisions and verify all information before acting on it."

To: r. peter Dale who wrote (37)	12/15/2000 3:28:54 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 78

Friday December 15, 3:05 pm Eastern Time Press Release SOURCE: Fountain Pharmaceuticals, Inc. Fountain Pharmaceuticals, Inc. Announces Resignation of President/CEO LARGO, Fla., Dec. 15 /PRNewswire/ -- Fountain Pharmaceuticals, Inc. (OTC Bulletin Board: FPHI - news) announces that Gerald Simmons, President & CEO, has resigned effective December 1, 2000. The Board of Directors has accepted his resignation and will begin a search for a successor immediately. Mr. Simmons has accepted the position of Managing Partner for The Planning Board LLC, a California-based E-Business consulting firm specializing in e-commerce strategy and marketing communications. Mr. Simmons has been President & CEO of Fountain since December 1998. Fountain Pharmaceuticals, Inc. is a research-oriented company seeking to exploit topical and other applications for its proprietary liposome technology. It markets products domestically under the LyphaZome® and Celazome® tradenames. Fountain Pharmaceuticals is also engaged with several global partners who market LyphaZome-based products with their own trade names under licensing agreements. Certain statements herein that are not historical and are forward-looking statements and involve risk and uncertainties. Although management believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that these expectations will prove to have been correct. Investors who seek more information about the company's business and relative risk factors may wish to review the Company's periodic reports including, but not limited to, its most recent Annual and Quarterly Reports. SOURCE: Fountain Pharmaceuticals, Inc.